Curamir Therapeutics
Woburn
About Curamir Therapeutics
Curamir is a Woburn, MA-based biotechnology company launched and incubated by Delos Capital with an initial academic licensing from SUNY. Through its proprietary miRNA engineering platform and insights into cancer biology, Curamir develops miRNA-based cancer therapeutics with enhanced safety, potency and stability. Its novel approach addresses current challenges associated with both chemoresistance in cancer and effective systemic delivery of miRNA mimics.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $10.0M
- Funding stage: Early Stage Venture
- Last round: Series A (Sep 2019)
- Website: curamirtherapeutics.com
Industries & Categories
Biotechnology, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/curamir-therapeutics-29633 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.